TLOG has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TLOG has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
TetraLogic Pharmaceuticals's change in inventory for the quarter that ended in Sep. 2016 was $0.00 Mil. It means TetraLogic Pharmaceuticals's inventory stayed the same from Jun. 2016 to Sep. 2016 .
TetraLogic Pharmaceuticals's change in inventory for the fiscal year that ended in Dec. 2015 was $0.00 Mil. It means TetraLogic Pharmaceuticals's inventory stayed the same from Dec. 2014 to Dec. 2015 .
TetraLogic Pharmaceuticals's Total Inventories for the quarter that ended in Sep. 2016 was $0.00 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
The historical data trend for TetraLogic Pharmaceuticals's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TetraLogic Pharmaceuticals Annual Data | |||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | ||||||
Change In Inventory | - | - | - | - | - |
TetraLogic Pharmaceuticals Quarterly Data | |||||||||||||||||||
Dec11 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | |
Change In Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TetraLogic Pharmaceuticals (OTCPK:TLOG) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
TetraLogic Pharmaceuticals's Days Inventory for the quarter that ended in is calculated as:
Days Inventory | = | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= | N/A |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
TetraLogic Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2016 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0 | / | 0 | |
= | N/A |
3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
TetraLogic Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2016 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 0 | |
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of TetraLogic Pharmaceuticals's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Hudson Bay Capital Management Lp | other: See Remarks | 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Lazard Asset Management Llc | other: See Remarks | 30 ROCKEFELLER PLZ, 56TH FL., NEW YORK NY 10112 |
Nomura Holdings Inc | other: See Remarks | 1-13-1 NIHONBASHI, CHUO-KU, TOKYO M0 103-8645 |
Whitebox Multi-strategy Partners Lp | other: See Remarks | 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416 |
Pandora Select Partners, L.p. | other: See Remarks | 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416 |
Whitebox General Partner Llc | other: See Remarks | 3033 EXCELSIOR BLVD., SUITE 300, MINNEAPOLIS MN 55416 |
Highbridge Capital Management Llc | other: See Remarks | 277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172 |
Sander Gerber | other: See Remarks | C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830 |
Whitebox Concentrated Convertible Arbitrage Partners, L.p. | other: See Remarks | 3033 EXCELSIOR BOULEVARD, SUITE 300, MINNEAPOLIS MN 55416 |
Whitebox Advisors Llc | other: See Remarks | 3033 EXCELSIOR BLVD., SUITE 500, MINNEAPOLIS MN 55416 |
Patrick Hutchison | officer: CFO & Treasurer | C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803 |
Clarus Ventures Ii, Llc | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Clarus Lifesciences Ii, L.p. | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Clarus Ventures Ii Gp, L.p. | 10 percent owner | 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142 |
Nicholas Simon | 10 percent owner | 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.